Siscovick D S, Schwartz S M, Corey L, Grayston J T, Ashley R, Wang S P, Psaty B M, Tracy R P, Kuller L H, Kronmal R A
Department of Medicine, University of Washington, Seattle, USA.
Circulation. 2000 Nov 7;102(19):2335-40. doi: 10.1161/01.cir.102.19.2335.
Whether serological evidence of prior infection with Chlamydia pneumoniae, herpes simplex virus type 1 (HSV-1), and cytomegalovirus (CMV) is associated with myocardial infarction (MI) and coronary heart disease (CHD) death remains a source of controversy.
We conducted a nested case-control study among participants in the Cardiovascular Health Study, a cohort study of persons aged >/=65 years. Cases experienced an incident MI and CHD death (n=213). Control subjects were matched to cases by age, sex, clinic, year of enrollment, and month of blood draw (n=405). Serum was analyzed for IgG antibodies to C pneumoniae, HSV-1, and CMV. After adjustment for other risk factors, the risk of MI and CHD death was associated with the presence of IgG antibodies to HSV-1 (odds ratio [OR] 2.0, 95% CI 1.1 to 3.6) but was not associated with the presence of IgG antibodies to either C pneumoniae (OR 1.1, 95% CI 0.7 to 1.8) or CMV (OR 1.2, 95% CI 0.7 to 1.9). Although there was little association with low to moderate C pneumoniae antibody titers (</=1:512), high-titer (1:1024) C pneumoniae antibody was associated with an increased risk (OR 2.2, 95% CI 1.1 to 4.4).
Among older adults, the presence of IgG antibodies to HSV-1 was associated with a 2-fold increase in the risk of incident MI and CHD death. For C pneumoniae, only high-titer IgG antibodies were associated with an increased risk of MI and CHD death. The presence of IgG antibodies to CMV was not associated with risk among the elderly.
既往感染肺炎衣原体、1型单纯疱疹病毒(HSV-1)和巨细胞病毒(CMV)的血清学证据是否与心肌梗死(MI)及冠心病(CHD)死亡相关仍存在争议。
我们在心血管健康研究的参与者中开展了一项巢式病例对照研究,该队列研究对象为年龄≥65岁的人群。病例组为发生首次MI及CHD死亡者(n = 213)。对照组按年龄、性别、诊所、入组年份和采血月份与病例组匹配(n = 405)。分析血清中针对肺炎衣原体、HSV-1和CMV的IgG抗体。在对其他危险因素进行校正后,MI及CHD死亡风险与HSV-1的IgG抗体存在相关(比值比[OR] 2.0,95%可信区间[CI] 1.1至3.6),但与肺炎衣原体(OR 1.1,95% CI 0.7至1.8)或CMV(OR 1.2,95% CI 0.7至1.9)的IgG抗体存在无关。尽管低至中度肺炎衣原体抗体滴度(≤1:512)相关性不大,但高滴度(1:1024)肺炎衣原体抗体与风险增加相关(OR 2.2,95% CI 1.1至4.4)。
在老年人中,HSV-1的IgG抗体存在与首次MI及CHD死亡风险增加2倍相关。对于肺炎衣原体,只有高滴度IgG抗体与MI及CHD死亡风险增加相关。CMV的IgG抗体存在与老年人的风险无关。